Table 3.

CEP data, QST z-values, and questionnaire scores for each patient group after age matching.

	FP		PNP		Significance level (p)
	n	mean ± SD	n	mean ± SD
N2 foot (ms)	10	499.3 ± 110.8 [420; 578.6]	8	668.1 ± 131.6 [558.1; 778.1]	0.016
P2 foot (ms)	10	596.8 ± 104.4 [522.1; 671.5]	8	771.6 ± 156.6 [640.7; 902.5]	0.012
Amplitude foot (µV)	11	7.6 ± 3.5 [5.2; 9.9]	11	5.5 ± 4.1 [2.8;8.3]	n.s.
PDQ score	13	18.46 ± 7.03 [14.21; 22.71]	13	15.77 ± 8.43 [10.68; 20.86]	n.s.
CDT foot Z value	13	−1.7 ± 1.2 [−2.4; −1]	13	−1.3 ± 1.4 [−2.1;0.4]	n.s.
MDT z-score	13	−1.3 ± 1.2 [−2; −0.6]	13	−2.8 ± 1.5 [−3.7; −1.9]	0.012
MPT z-score	13	1.5 ± 1.1 [0.8; 2.2]	13	−0.2 ± 2.8 [−1.9; 1.6]	0.01
VDT z-score	13	−0.5 ± 1.5 [−1.4; 0.4]	13	−3.8 ± 2 [−5; −2.6]	<0.001
HR variability resting		4.4 ± 2.5 [2.9; 5.9]		3.3 ± 1.6 [2.3; 4.2]	n.s.
RMSSD resting		28.8 ± 15.8 [19.2; 38.4]		21.9 ± 10.8 [15.3; 28.4]	n.s.
HR variability breathing		8.9 ± 5.1 [5.8; 11.9]		8.2 ± 7.3 [3.7; 12.6]	n.s.
RMSSD breathing		41.6 ± 20.6 [29.2; 54]		41.2 ± 28.7 [23.8; 58.5]	n.s.
Orthostatic TDM		1.3 ± 0.4 [1; 1.5]		1.2 ± 0.2 [1.1; 1.3]	n.s.

Group comparisons have been performed with the Mann–Whitney U-test and p-values shown as “significance level.” FD, patients with Fabry disease; PNP, patients with polyneuropathy; PDQ, painDETECT questionnaire; QST, quantitative sensory testing; RMSSD, root mean square of successive square differences; TDM, time-domain measurement; VDT, vibration detection threshold; CDT, cold detection threshold; CEP, cold-evoked potential; HR, heart rate; MDT, mechanical detection threshold; MPT, mechanical pain threshold. The lower and upper 95% confidence limits are presented in brackets below the mean ± standard deviation. Note that there are discrepancies between the patient numbers for latencies and amplitudes. This results from the circumstance that some patients presented clearly abolished potentials, to whom we assigned an amplitude of 0 µV.